Supplementary Figure S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Holger N. Lode; Nikolai Siebert; Dominique Valteau‐Couanet; Alberto Garaventa; Adela Cañete; John W. Anderson; Isaac Yaniv; Shifra Ash; Juliet C. Gray; Thomas Klingebiel; Hans Loibner; Roberto Luksch; Carla Manzitti; Jean Michon; Cormac Owens; Ulrike Pötschger; Sascha Troschke‐Meurer; Evgenia Glogova; Ruth Ladenstein

doi:10.1158/1078-0432.30028892

Key Points

Younger patients with neuroblastoma had different event-free survival rates based on fcgamma receptor polymorphism, and it highlights age as a critical factor.
The analysis revealed that differences in overall survival were noticeable in patients based on natural killer cell levels, with significant implications for treatment strategy.
Event-free survival and overall survival metrics were directly correlated with age and NK cell levels, suggesting immune factors play a vital role in response to treatment.
Findings indicate potential adjustments in neuroblastoma treatment regimens based on individual patient characteristics, particularly their age and NK cell responses.

Implication

Observational analysis shows differing outcomes in neuroblastoma patients by age and NK cell levels, suggesting treatment adaptation may be necessary.

Abstract

Supplementary Figure S3. Event-free survival and overall survival by age ≤5 years and >5 years (A and B) and by NK cells on day 15/cycle 1 above or below the median level (C and D). EFS, event-free survival; OS, overall survival; NK, natural killer; SE, standard error.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lode et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd029cf https://doi.org/10.1158/1078-0432.30028892

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers